Development of nanoparticle (NP) based therapies to promote regeneration in sites of central nervous system (CNS; i.e. brain and spinal cord) pathology relies critically on the availability of experimental models that offer biologically valid predictions of NP fate in vivo. However, there is a major lack of biological models that mimic the pathological complexity of target neural sites in vivo, particularly the responses of resident neural immune cells to NPs. Here, we have utilised a previously developed in vitro model of traumatic spinal cord injury (based on 3-D organotypic slice arrays) with dynamic time lapse imaging to reveal in real-time the acute cellular fate of NPs within injury foci. We demonstrate the utility of our model in revealing the well documented phenomenon of avid NP sequestration by the intrinsic immune cells of the CNS (the microglia). Such immune sequestration is a known translational barrier to the use of NP-based therapeutics for neurological injury. Accordingly, we suggest that the utility of our model in mimicking microglial sequestration behaviours offers a valuable investigative tool to evaluate strategies to overcome this cellular response within a simple and biologically relevant experimental system, whilst reducing the use of live animal neurological injury models for such studies.
Nano Res. 2016, 9(8): 2384-2397 such studies have neglected to consider the role of the immune component of the nervous system itself. From research in recent years it has become apparent that such delivery strategies will need to take account of a major barrier to therapeutic NP delivery imposed by these resident immune cells of the brain and spinal cord-namely the "microglia" [5] [6] [7] . Microglia are highly phagocytic and motile immune cells present throughout the central nervous system (CNS), and are involved in constant surveillance of their local microenvironment for identification and removal of "foreign" material [7, 8] . Microglia have been shown to dominate uptake versus other neural cell types due to their comparatively rapid and extensive particle uptake profiles [9] . This has been demonstrated for different NP types, using defined glial co-cultures [9] , undefined co-cultures of primary neurons and glial cells, and more complex transverse organotypic spinal cord slices (intact tissue) co-cultured with peripheral nerve grafts [10] . Together, it is estimated that the glial cells account for up to 99.5% of cellular uptake of NPs, with microglia shown to be responsible for the majority of this uptake in vivo [11] . The high clinical relevance of this phenomenon is reflected in in vivo studies that replicate these observations of microglial dominance of uptake following direct delivery of NPs to the CNS [11] [12] [13] . Injection of aminosilane-coated superparamagnetic iron oxide NPs (core diameter 15 nm) into glioblastoma tumours for thermotherapy reveals that the NPs are overwhelmingly localised in microglia/macrophage-like cells [13] . In striking contrast, other cell types in the brains of these patients, such as the target glioblastoma cells and reactive astrocytes rarely displayed intracellular NPs. This result is not due to tumour cells lacking the capacity for NP uptake, as experiments using isolated gliosarcoma and glioma cells in vitro (i.e. in the absence of microglial cells) demonstrate that tumour cells can take up NPs-observations which would have erroneously predicted efficient tumour cell uptake in the intact CNS [12] . Similarly, when injected into sites of transecting spinal cord injury (SCI) in rodents, Spherofluor NPs (approx. 360 nm diameter) showed localisation exclusively to immune cells (our unpublished data). We have also shown that in line with their phagocytic roles, microglia inactivate particles by sequestration into vesicles and extensive lysosomal degradation [14] .
Such observations highlight an important clinical challenge confronting NP delivery into the CNS particularly for sites of neurological injury and disease where large numbers of activated microglia exist. They additionally highlight the need for the development of multicellular experimental model systems, wherein post-injury pathological processes and the microglial barrier can be effectively replicated, for the developmental testing of therapeutic approaches to overcome the barrier imposed by microglial clearance. Live animal neurological injury models represent the most biologically relevant experimental systems in this context, but the relative inaccessibility of the brain and spinal cord for experimental manipulation necessitate highly invasive procedures with several attendant ethical and practical drawbacks [11, [15] [16] [17] . There is therefore a major need for alternative, biomimetic models to Reduce, Refine and Replace live animal use in neuro-nanotechnology studies [18] . Despite this need, studies demonstrating competitive microglial clearance and the related barrier to uptake in other neural cell types have generally used simple, undefined co-culture systems [10] which overall fail to replicate the complex cyto-architecture of neural tissue [19] . It should also be noted that all of these previous studies did not incorporate a neurological injury component and are therefore limited in their ability to mimic the intricate environment of neurological injury sites, wherein multiple cell types with specialised functions co-exist.
In this context, a novel in vitro model of SCI described by ourselves recently could provide a technically facile but valuable experimental tool for studying microglial particle uptake dynamics within an injury-simulated environment [20] . This model is based on the use of 3-D spinal cord tissue arrays within which a focal, traumatic injury can be induced severing the nerve fibres, mimicking for example injuries due to knife/gunshot wounds. We previously demonstrated that major pathological features of neurological injury in vivo, such as the formation of a glial cell scar and an age related decline in nerve fibre regeneration were all mimicked in the injury focihighlighting the model's relevance to CNS injury in vivo [20] . Importantly, injury foci were found to Nano Res. 2016, 9(8): 2384-2397 be progressively infiltrated by microglial cells which showed highly activated phenotypes characteristic of pathological sites. Despite the neuro-mimicry offered by the model, it is not known whether it can be used to replicate competitive sequestration of NPs by microglia in neural pathology sites, or to mimic intercellular differences in NP uptake profiles as seen in vivo. If such a demonstration can be shown to be successful, then our model could provide a powerful tool to study the microglial barrier and investigate pharmaceutical approaches to overcome it. Here, we have delivered a well-characterised NP into spinal cord slice injury sites; using a combination of dynamic live-cell and confocal imaging, we document cellular particle uptake and sequestration profiles by the microglia versus other major neural cell populations in the simulated injury foci.
Materials and methods
The care and use of animals was in accordance with the Animals (Scientific Procedures) Act of 1986 (UK) with local ethics committee approval.
Reagents and equipment
Tissue culture plastics, media and supplements were from Fisher Scientific (Loughborough, UK) and Sigma Aldrich (Poole, UK). Millicell culture inserts (PICM0RG50) and Omnipore membranes (JHWP04700) were from Millipore (Watford, UK). Spherofluor (Sphero TM ) magnetic NPs (comprising a polystyrene core stained with the fluorescent dye Nile red, within a composite layer of polystyrene and iron oxide, coated with carboxylic acid groups) were obtained from Spherotech Inc. (Lake Forest, Illinois, USA). The NP used in this study has been shown to accumulate in areas of transecting SCI (the in vivo counterpart to the injury model used in the current study and which is associated with breakdown of the blood-spinal cord barrier) after intravenous delivery in rodents [21] , and has been well-characterised by electron microscopy, zeta-sizer analysis, powder X-ray diffraction and Fourier transform infrared spectroscopy (200-390 nm diameter, mean 360 nm; -14 mV zeta-potential; iron content 15%-20% w/v) [14] . The live/dead cell viability kit was from Invitrogen (Paisley, UK). Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories (Peterborough, UK). Primary antibodies were: rat anti-CD11b (clone 5C6, MCA711GT; Bio-Rad, UK), rabbit anti-Cx 3 cr1 (TP501; amsbio, UK), rabbit anti-glial fibrillary acidic protein (GFAP) from DakoCytomation (Ely, UK), rat anti-myelin basic protein (MBP) from Serotech (Kidlington, UK) and rabbit anti-neuronal class III β-tubulin (clone TUJ-1) from Covance (Princeton, NJ). Fluorescein isothiocyanate (FITC)-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA), except FITC-conjugated anti-biotin secondary antibody, which along with biotin-conjugated lectin (from Lycopersicon esculentum) and dexamethasone (DEX) 21-phosphate disodium (D4902; ≥97% pure) was from Sigma Aldrich (Poole, UK).
Preparation and lesioning of organotypic spinal cord slice cultures
Spinal cord slice cultures were generated and lesioned as described previously [20, 22, 23] . Briefly, mouse pups aged 1-3 postnatal days (P1-3) were terminally anaesthetised, decapitated and a midline incision was made along the length of each spine. The spinal cords (approximately 10 mm in length) were rapidly dissected out from the thoracolumbar region and placed in ice-cold slicing medium (Earle's balanced salt solution, EBSS, buffered with 25 mM HEPES). The cords were transferred onto the chopping plate of a McIlwain tissue chopper and sliced lengthways in the parasagittal plane (350 μm thickness) to produce five to seven usable slices per cord. Intact slices were transferred to Omnipore membranes, resting on the Millicell culture insert membrane within 35 mm Petri dishes ( Fig. 1(a)(1) ). Slices were cultured at the airmedium interface with an 80% medium change every two days (50% modified Eagles' medium (MEM), 25% heat-inactivated horse serum, 25% EBSS supplemented with 36 mM D-glucose, 100 U·mL -1 penicillin, 100 μg·mL -1 streptomycin and 250 ng·mL -1 amphotericin B). Cultures were incubated in 5% CO 2 /95% humidified air at 37 °C for a total of six days in vitro (DIV). Nano Res. 2016, 9(8): 2384-2397 (1) Mouse spinal cords were sliced in the longitudinal parasagittal plane and cultured within inserts for a total of 6 DIV. Slices were lesioned at 1 DIV using a double-bladed scalpel. (2) NPs were added into slice lesions at 6 DIV using a P2 Gilson pipette and a dissection microscope at ×12.5 magnification. (3) Slices were maintained in an incubation chamber, and imaged for 6-24 h using an upright time-lapse microscope. The lesioning procedure (Figs. 1(a)(1) and 1(b)) was conducted within a laminar flow hood using a dissection microscope at ×12.5 magnification. Slices were focally lesioned using a double-bladed scalpel (size 15 surgical blades) with small lateral movements made to ensure the complete severance of nerve fibre tracts. The slice debris between the two lesion margins was subsequently removed using an aspirator, fitted with a 200 μL pipette tip, leaving well-defined lesion margins (verified by microscopic analysis) approximately 440 μm apart. This allows for easy visualisation of cellular NP uptake dynamics within the injury site. Spinal cord slices were lesioned at 1 DIV then maintained until 6 DIV for all experiments, as a peak in microglial infiltration has previously been shown by ourselves to occur at five days post-lesioning [20] .
Delivery of NPs into lesioned slices
A dissection microscope at ×12.5 magnification and a manual pipette were used to deliver Sphero NPs (suspended in fresh slice culture medium at 20 μg·mL -1 ; 0.75 μL dose) into the lesion of each slice (Figs. 1(a)(2) and 1(c)). The feasibility of using an automated NP delivery device (i.e. Nanoject II TM AutoNanoliter Injector) was assessed (data not shown), but due to the prolonged setup time and additional experimental manipulations required, a manual pipette was considered sufficient for this study. Slices were incubated with NPs for 6 h, as substantial cellular uptake occurs within this time period [14, 24, 25] . All slices were fixed in 4% paraformaldehyde (PFA; 20 min; room temperature (RT)). The NP concentration and volume applied was optimised in pilot experiments, as volumes greater than 1 μL resulted in lateral spread of NPs around the lesioned slice, and NP concentrations lower than 20 μg · mL -1 limited the NPs available for cellular uptake within the lesion site, hindering quantification of uptake (data not shown).
Time-lapse imaging experiments
Lesioned spinal cord slices (within 35 mm Petri dishes) at six DIV were placed in an incubation chamber (preheated to 37 °C ; 5% CO 2 /95% humidified air; Figs. 1(a)(3), 1(d) and 1(e)) on an upright time-lapse microscope (Axiozoom V16, AxioCam ICm1 camera; Nano Res. 2016, 9(8): 2384-2397 Carl Zeiss, Germany). Time-lapse imaging commenced within 10 min of NP addition. Lesioned slices without NPs were similarly recorded at 6 DIV to observe the cellular activity within injury sites. For all experiments, transmitted light images (auto exposure; average 6 ms) were captured every 2 min, with counterpart fluorescence imaging (fixed at 50 ms) for NP addition experiments. Z-stack imaging was used at each timepoint to allow compensation for the limited focal drift observed in pilot experiments. Video files from each imaging session were created using ZEN software (Blue Ed., v.1.1.1.0, Carl Zeiss, Germany) and Premiere Elements 7 (Adobe, USA).
Assessment of lesioned slice viability post-live cell imaging
To assess whether the imaging procedures had adverse effects on slice viability, control lesioned slices without NPs were stained following time-lapse imaging experiments (n = 4) and DEX treatment (n = 3). The high viability (ca. 96%) of control unlesioned slices was previously demonstrated. Slices were washed three times in phosphate buffered saline (PBS) and incubated for 15 min at 37 °C with calcein (1 μL·mL -1 ) and ethidium homodimer (3 μL·mL -1 ) to label live and dead cells respectively. Slices were washed three times in PBS and mounted in Vectashield mounting medium with DAPI. Consistent camera exposure settings were used for both fluorescent channels, with images converted to grayscale. Corrected integrated density measurements were performed using ImageJ software (version 1.45s; NIH) and the values for the live stained micrograph expressed as a percentage of the sum total from both [20, 26] .
DEX treatment of slices to induce microglial suppression
For microglial suppression experiments, an 80% medium change was performed at 1 DIV and every two days thereafter with culture medium containing DEX (10 μM final concentration). This concentration is within the range that has previously been shown to maximally affect various cell types in vitro [27, 28] . Additionally, 5 μL of DEX culture medium was applied daily directly into slice lesions to ensure sustained delivery of drug within the lesion site. This small volume was used to limit the quantity of medium covering the slices, a critical factor in the maintenance of slice viability at the air-medium interface [22, 23] . The overall viability of live/dead stained control slices treated with DEX was quantified to assess the safety of the method of treatment.
Comparative NP incubations with isolated high purity astrocyte populations
NP uptake experiments have previously been performed in our lab using high purity astrocyte cultures (ca. 98% GFAP + ) derived from cerebral cortices of neonatal Sprague-Dawley rats using an established procedure [29] . Briefly, enzymatically-detached astrocytes were plated on poly-D-lysine (PDL)-coated coverslips (4 × 10 4 cells · cm -2 ) in D10 medium (Dulbecco's modified Eagle's medium, 1 mM sodium pyruvate, 50 mg·mL -1 streptomycin, 50 U·mL -1 penicillin, 10% fetal bovine serum and 2 mM glutaMAX-I) at 37 °C in humidified 5% CO 2 /95% air. After 24 h, Sphero NPs were added at 20 ng·mL -1 and incubated for 4 h, then fixed and immunocytochemically stained as detailed below. The date from these experiments was used to demonstrate the differences in NP uptake when using isolated purified cells, versus those in the injury simulated environment containing microglia.
Immunocytochemistry
Slices were washed three times in PBS before and after fixation with 4% PFA (20 min; RT). Samples were incubated in blocker consisting of 5% normal donkey serum (10% for lectin staining) in PBS (with 0.3% Triton X-100 for TUJ-1, MBP and GFAP staining), with lectin (1:200 in blocker) or primary antibodies (TUJ-1 1:1,000; MBP 1:200; GFAP 1:500; CD11b 1:125; Cx 3 cr1 1:100; 24 h at 4 °C ). Following three PBS washes, samples were incubated with appropriate FITCconjugated secondary antibodies (4 h at RT or 4 °C ). Slices were subsequently washed three times with PBS and mounted with Vectashield mounting medium containing DAPI.
Fluorescence imaging: Fixed slices
Slices were visualised at ×200 magnification on an Nano Res. 2016, 9(8): 2384-2397 Axio Scope A1 fluorescence microscope (Carl Zeiss MicroImaging GmbH; Germany) fitted with an Axio Cam ICc1 digital camera and AxioVision software. Where applicable, fluorescence images of immunostained slices were merged/stitched using Photoshop CS5.1 (version 12.1) allowing assessment of entire lesions.
Quantification of microglial infiltration (± DEX treatment)
The total number of lectin-reactive (lectin + ) microglia within each lesion was divided by the total area of the lesion (mm 2 ) to account for differences in slice width (dorsal-ventral). Average values for microglial density were calculated for lesions within DEX-treated and control slices (n ≥ 4 per group).
Assessment of extent of NP uptake within lesioned slices within microglia and astrocytes
NP-labelled astrocytes and microglia (GFAP + and lectin-reactive respectively; the neural cell types with the most extensive particle uptake profiles in isolated cell cultures) were counted within lesion areas and expressed as a percentage of the total number of cells (n ≥ 3 per group). The extent of NP accumulation in individual cells was assessed semi-quantitatively by comparing the area of NP accumulation with the average cross-sectional area of an astrocyte or microglial nucleus, as appropriate using a previously validated method for nanoparticle uptake quantification [14] . The extent of NP uptake by each cell was scored as: "low" (less than 10% of the average area of a nucleus); "medium" (10%-50%); or "high" (>50%). Only NPs that were clearly intracellular were included in analyses.
Statistical analysis
The number of experiments, n, refers to slices obtained across different animals and litters. Prism v5.0 software (GraphPad, USA) was used for statistical analyses. Data are expressed as mean ± standard error of the mean (SEM). Live/dead viability analysis: Student's t-test (two-tailed) with Welch's correction was used to compare viability of lesioned slices following recording or DEX treatment. Microglial infiltration analysis: Student's t-test (two-tailed) was used to compare microglial infiltration ± DEX treatment. NP uptake analysis: Data were square root transformed and a oneway analysis of variance (ANOVA) conducted using Bonferroni's multiple comparison test for post-hoc analysis (a Bartlett's test was performed to examine homogeneity of variance) to detect differences in astrocyte and microglial NP uptake ± DEX treatment. Extent of NP uptake analysis: Student's t-test (twotailed) with Welch's correction was used to detect differences in the extent of astrocyte and microglial NP uptake ± DEX treatment.
Results

Validation of NP delivery and time-lapse recording methodology
The use of a pipette for NP delivery into spinal cord slices proved to be a simple and effective method to achieve focal particle delivery into lesion sites ( Fig. 2(a) ). A dissection microscope facilitated accurate guidance of the pipette tip to the lesion site, and live assessment of the distribution of NP solution with respect to the lesion site. Fluorescence micrographs of live/dead stained slices captured immediately following time-lapse experiments ( Fig. 2(b) ) revealed a high proportion of viable cells in the body of the slice with the few dead cells typically located around the slice edges and in the vicinity of the lesion site, suggesting the procedure is without acute adverse effects. Indeed, lesioned slice viability following timelapse recording experiments was 95.8% ± 2.0% (live/ dead assay; n = 4), which is in accordance with our previous values for slices maintained in conventional incubators [20] .
Time-lapse recordings of NP uptake by cells within slice lesions and identification of cell phenotype
Recordings of control slices 5 days post-lesion induction revealed a population of highly motile cells with a rounded morphology within the margins of lesions (Video S1 in the Electronic Supplementary Material (ESM)) suggestive of a microglial phenotype; these cells also appeared to be highly proliferative (Fig. 3(a) and Video S2 in the ESM) with frequent cell divisions observed. Following the addition of NPs into lesion sites, rounded highly active cells could be observed to respond to particle addition with highly motile activity and engulfment with evidence of rapid membrane reorganisation (extrusion and withdrawal). This resulted in high accumulation of NPs by this cell population, and the extent of intracellular particle accumulations could clearly be seen to increase over the duration of the recordings (Figs. 3(b)-3(d) and Video S3 in the ESM). Post-imaging, it proved simple to identify cells whose behaviours were recorded in imaging studies through immunocytochemical staining for cell type-specific markers. This was achieved by marking (prior to fixation) the lesion edge from which recordings were made and noting distinctive anatomical features at the margin, including curvature of lesions, distinctive NP clusters and so on. Staining of slices post-recording clearly revealed this rounded motile population with prominent engulfing behaviours to be lectin-reactive microglia (Fig. 3(e) and Video S3 in the ESM).
Immunocytochemical staining of lesioned slices to identify cell populations showing NP internalisation
Detailed analyses were conducted in order to identify specific cell sub-types associated with NP uptake within lesions. In keeping with findings from time-lapse recordings ( Fig. 3(e) ), lectin-reactive microglia in slice lesions displayed large accumulations of NPs and had rounded morphologies, indicative of microglial activation (Fig. 4(a) ). In contrast the microglia found within the body of slices displayed multiple ramified processes characteristic of "resting" (non-activated) cells (Fig. 4(b) ). Microglial identity was confirmed Nano Res. 2016, 9(8): 2384-2397 using three specific markers: lectin, Cx 3 cr1 and CD11b (Fig. 4(b) ). Astrocytes in high purity 2-D cultures have previously been shown by us to extensively internalise Sphero NPs, following comparable incubation periods [14, 25] (same NP concentration; also see Fig. 4 (c) for internalisation by astrocytes in isolated, high purity primary-derived cultures). By contrast, astrocytes in slice cultures exhibited far lower NP uptake levels (in terms of both proportions of cells labelled and the extent of NP accumulation). Indeed, overall there was little evidence of NP uptake by the GFAP + astrocytes within the multicellular environment of the slice lesions, including at the lesion margins ( Fig. 4(d) ). Similarly, MBP + oligodendrocytes (Fig. 4(e) ) and TUJ-1 + neurons (Fig. 4(f) ), showed negligible particle uptake; in every instance, NP accumulations were overwhelmingly associated with cells that were negative for markers of these major neural cell types, highlighting that delivered NPs were almost exclusively localised to the microglial population.
Dexamethasone treatment reduces the infiltration and NP uptake profiles of microglia
DEX treatment of lesioned slices did not affect overall viability (live/dead assay; >97% fluorescence intensity being attributable to calcein (live cells) in all slices; two-tailed Student's t test versus lesioned slices without DEX ; n = 3), with the number of dead cells within and around the lesion site being similar to controls ( Fig. 5(a) ). Immunocytochemical staining of DEX treated lesioned slices showed low numbers of lectin -reactive microglia in lesion sites ( Fig. 5(b) ). Occasionally, microglial cells were observed with high levels of NP accumulation, comparable to slices without DEX (arrows in Fig. 5(b) ), but fewer cells exhibited NP uptake overall (compare Fig. 5(b) with Fig. 4(a) ). Compared to control slices without DEX, there was greater evidence of NP uptake by GFAP + astrocytes in lesions (compare Fig. 5(c) with Fig. 4(d)) .
Quantification of the extent of microglial infiltration into lesions showed reduced numbers of microglia following DEX treatment compared to untreated controls ( Fig. 5(d)) . A quantitative analysis of the proportions of microglia and astrocytes displaying NP labelling within lesion sites in the absence of DEX treatment ( Fig. 5(e) ) showed that a significantly greater percentage of microglia was labelled than astrocytes (ca. 5-fold more). In DEX treated slices, the proportion of microglia exhibiting NP uptake was significantly reduced. This percentage was still greater than the proportion of astrocytes labelled on average. Further, while visual observations revealed that astrocytes showed larger accumulations in DEX treated cultures, this was not found to be statistically significant. A semi-quantitative analysis of the extent of particle accumulation in NP-labelled cells (Fig. 5(f) ) shows predominantly "low" levels in astrocytes, with <5% of cells showing "medium" and no astrocytes exhibiting "high" levels of accumulation: This pattern of labelling did not change with DEX treatment. In comparison to astrocytes, microglia displayed cells with "high" and "medium" levels of labelling, with the percentage of cells exhibiting "medium" levels being significantly reduced with DEX treatment.
Discussion
Sequestration of particles delivered to the CNS parenchyma by the resident neural immune cells (the microglia), represents a major translational challenge confronting the delivery of NP-based therapeutics to areas of neurological injury and disease. As microglial sequestration is a critical determinant of the eventual fate of administered particles, experimental research critically requires model systems that simulate microglial responses to delivered therapeutic particles within a pathological environment. Here, we demonstrate the utility of our novel SCI model to examine the interactions of major neural cell types (that play key roles in injury and repair) with NPs within a site of neurological injury. Notably, we were able to demonstrate for the first time in real-time, the surveillance behaviours of intra-lesional microglia and their avid response to the delivered NPs. Such microglial clearance of nanotherapeutic agents is an important area for CNS drug discovery and nanotechnology research, but the rate of progress in this field is hampered by the absence of available experimental models in which the immune cell component of pathology sites can be adequately and easily mimicked. We consider that our model can serve as a valuable tool offering the technical ease of in vitro handling, with the pathological complexity of injury sites. Consequently, we consider that demonstration of the handling of nanoparticles by slice microglia, with proof of similarities to the in vivo situation (as shown in this study) is an important outcome, and can be predicted to be of high use in translational and pharmaceutical studies. This could be via the use of immune suppressive treatment (that can alter microglial numbers/function, as shown here), the use of the so called "stealth coatings" to evade immune cell uptake or even stem cell transplantation that has been suggested to reduce immune activation, highlighting the versatility of our model for therapeutic testing.
Importantly, we prove using the model that administration of an anti-inflammatory drug (DEX) that is currently used widely in clinical neurology, including for the treatment of acute SCI, can reduce the infiltration of the injury site by microglia, a phenomenon that is entirely consistent with the reported effects of DEX in vivo [30] . In turn this reduction in the cellular response of microglia was clearly shown to limit their sequestration of NPs. This highlights the utility of our "reductionist" model for the developmental testing of pharmaceutical strategies to limit the sequestration of therapeutic NPs by neural immune cells.
A few different approaches have been taken to mimic SCI pathology in vitro including: monoculture systems (primary and cell lines), co-culture systems, microfluidic devices and organotypic slice cultures [31] [32] [33] [34] [35] [36] [37] . A number of factors must be taken into consideration when evaluating the utility of each model system including the ability to mimic intercellular Nano Res. 2016, 9(8): 2384-2397 uptake dynamics, definition of cellular ratios to model specific CNS regions/disease states, standardisation of protein coronas around introduced nanoparticles, ease of nanoparticle delivery, and amenability to various (including real-time) imaging techniques [9] . Microfluidics models usually (and mono-cultures by definition) do not contain all the major cell types present in the CNS and thus fail to mimic the complex multi-faceted components of SCI pathology, which limits their value in the context of NP uptake experiments. Co-culture systems often do not contain microglial cells, a significant omission given their dominant uptake profiles, and usually also lack simulated injury [9, 14] . A few laboratories have simulated SCI in organotypic spinal cord slice cultures, which contain multiple cell types within in vivo-relevant cytoarchitecture. However, two of these models were established by weight drop onto slices, which is not suitable for assessing NP uptake in clearly-demarcated lesion sites, and while these models mimicked some of the responses to injury in vivo overall the characterisation of pathology was basic (e.g. cell death) [33, 36] . Another SCI model has been established based on induction of complete transecting injury in parasagittal organotypic spinal cord slices from neonatal mice [23] . However, cardinal neuropathological responses were only characterised in the neurons, neglecting neuroglial responses. An elegant model has been established that contains neurons and the major neuroglial cells, by seeding dissociated rat embryonic spinal cord on top of an astrocyte monolayer [37] . The mechanical induction of injury resulted in a lesion site with many of the cardinal pathological responses displayed by multiple cell types (demyelination, reactive astrocytosis, neurite degeneration and, importantly, microglial infiltration). This model is better defined and the induced injury produces a lesion site better-suited to NP uptake studies than the other models reported. However, we suggest that the cytoarchitecture of the spinal cord and potentially, therefore, some of the complex cell-ECM signalling present in vivo, is better mimicked in organotypic slice cultures. Indeed, in the context of model development for laboratory research, it has recently been suggested that the best experimental predictability is offered by organotypic slice models that can replicate the microenvironment of the donor tissue [38] . Our model is consistent with this paradigm. We consider therefore that the system developed by ourselves can provide clinically relevant insights into the fate of NPs delivered to neuropathology sites. Our injury-simulating model offers major benefits for regenerative neurology as a neuromimetic screening system given: (a) The full complement of neural cell subclasses is present in the slice arrays and can be easily detected using standard procedures; (b) the use of humane procedures to derive tissue and reduce reliance on live animal experiments; (c) the simplicity/ cost effectiveness of the methods and reagents used; (d) several slices (up to seven) can be derived from a single animal at the donor ages used, significantly reducing animal usage; (e) reduced biological variability as both experimental and control slices can be derived from the same animal; (f) the derivation of organotypic spinal cord slices from human tissue has been proved feasible highlighting the clinical utility of the model [39] ; (g) the ease of experimental manipulation and compatibility of the model with a wide range of imaging methods, including time lapse and confocal microscopy. The compatibility of timelapse imaging whilst retaining slice viability was verified by live/dead staining; the capture of cellular NP uptake events within slice lesion sites also proved feasible. Introduction of NPs into the injured tissue was simple and rapid to perform, demonstrating the versatility of the injury model, which can therefore be used to study cellular interactions with a wide range of NPs/materials. Further, post-culture immunostaining of slices facilitated the direct identification of timelapse imaged cells and permitted the assessment of NP uptake across different cell types. Less obviously, a single growth medium is required to culture the slices, overcoming issues related to differential biomolecular corona formation when different biological media are used to culture individual cell types [9] . This can significantly affect NP uptake and is a major confounding factor in comparative and cross-cellular studies of NP uptake [9, 10] .
While microglia will present a critical challenge for delivery strategies to the CNS, this is currently a poorly studied area in neuro-nanotechnology. Such impediments to the clinical translation of therapeutic nanoparticles raise important issues regarding the necessity to develop interventions to overcome the microglial barrier (in order to enhance bioavailability to other target neural cell types in the CNS). Clearly, the use of immunosuppressive or immunomodulatory therapies to reduce microglial activity could constitute one such clinically relevant approach. In this regard, the corticosteroid DEX is commonly prescribed as an immunosuppressive therapy following injuries to the CNS [40, 41] and acts by inhibiting microglial proliferation [42] , reducing their migratory capabilities [43] and potentially increasing microglial apoptosis [44, 45] . In keeping with this role of DEX in vivo, we observed a significant reduction in the numbers of microglia in slice lesion sites. The extent of NP accumulation within microglia was also reduced-which would have predicted increased extracellular availability of NPs to other neural cell types. However, in our study we observed only the suggestion of an increase in astrocyte labelling with no apparent enhancement of particle uptake in other neural cell types. The reasons for this lack of effect are not clear at present, and DEX-induced impairment of endocytic processes in other (non-microglial) neural cell types cannot be ruled out. The use of different immunosuppressive drugs and longer treatment regimens would prove interesting in this regard. In this context, we recently showed that even when a small population of microglia (less than 5%) are present within high purity monocultures of astrocytes, oligodendrocyte precursors and oligodendrocytes, NP uptake by the non-microglial cells is dramatically limited due to avid microglial sequestration [10] . This underscores the highly responsive nature of the microglial response, for identification and removal of foreign materials from the CNS. Consequently, even a small residual population of microglia within the lesion sites persisting after DEX treatment may have been sufficient to dramatically limit particle uptake in other cell types.
Nonetheless, our findings do highlight the utility of our model as a screening system for strategies that promote evasion of the neural immune component, in order to optimise the use of NP-based approaches for neuropharmacology and nanotherapeutics. We consider that the use of similar experimental models based on 3-D organotypic slices derived from other types of biological tissues, has great potential for the screening of nanotherapeutic agents for a spectrum of disease and injury. As such, we consider that our approach has high relevance to the nanotechnology community in the developmental testing of pharmaceutical interventions based on nanotherapeutic agents.
Conclusions
We demonstrate the multiple advantages offered by a 3-D simulation of SCI (based on organotypic slice cultures of spinal cord tissue), to examine the fate of NPs delivered into areas of neural pathology, specifically their uptake by the resident immune cells. Dynamic live-cell imaging and histological assessment following NP delivery into slice injury sites revealed in real-time the well-documented phenomenon of competitive sequestration of particles by infiltrating microglia-a process that markedly reduced uptake in other neural cells in the injury sites. Use of immunosuppressive DEX-treatment proved to be an effective means to reduce microglial sequestration of particles. These results provide a real-time demonstration of the major intrinsic neural immune barrier that exists in the context of CNS-targeted nanotherapeutics. Our biological model therefore provides an alternative platform to test strategies to promote evasion of microglial clearance of biomaterials whilst reducing the use of live animal injury models for developmental testing of such interventions, in nanotechnology research. Nano Res. 2016, 9(8): 2384-2397 microglial motility and proliferation within lesion sites ± NPs) is available in the online version of this article at http://dx.doi.org/10.1007/s12274-016-1125-7.
